Emerson Electric
EMR
$158.71
+0.28%
Emerson Electric Co. is a global industrial technology leader that designs and manufactures automation software, valves, gauges, switches, and power tools for a wide range of industries, including manufacturing, energy, and chemical processing. The company has transformed itself into a pure-play industrial automation player through strategic divestitures of its climate technology and consumer businesses, positioning it as a key enabler of the factory automation trend. Currently, investor attention is focused on Emerson's ability to sustain growth in its core automation segments, its margin expansion initiatives, and its strategic pivot toward higher-margin software and systems, which are seen as critical to long-term value creation. The stock has also been in the spotlight due to recent price momentum and analyst actions, reflecting optimism about its transformation and end-market recovery.…
EMR
Emerson Electric
$158.71
Investment Opinion: Should I buy EMR Today?
Based on the analysis, Emerson is rated a 'Buy' with a thesis that the company's transformation into a pure-play automation leader, combined with reasonable forward valuation and improving margins, will drive earnings growth and stock appreciation. The analyst consensus is 'Buy' with an average target of $163.48, implying a 4.2% upside, but the high target of $203 suggests significant upside potential if execution is strong.
Sign up to view all
EMR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Emerson's fundamentals are solid, but the stock's recent underperformance relative to the market and the wide analyst target range introduce uncertainty. The forward valuation is fair, and the company's strategic focus on automation is a positive. However, the modest revenue growth and high trailing PE suggest limited upside in the near term. The stance would be upgraded to bullish if revenue growth accelerates above 5% or if the stock pulls back to below $140, and downgraded to bearish if earnings miss or macro conditions deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $170.07 and implied upside of +7.2% versus the current price.
Average Target
$170.07
0 analysts
Implied Upside
+7.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $205
Analyst target range
The target price range spans from a low of $104.00 to a high of $203.00, reflecting a wide dispersion in analyst expectations. The high target of $203.00 implies an upside of 29.4% from the current price, likely assuming strong execution of the automation strategy, margin expansion, and a favorable industrial cycle. Conversely, the low target of $104.00 suggests a downside of 33.7%, which could be based on concerns about a potential economic slowdown, competitive pressures, or integration risks. The wide spread between the low and high targets indicates significant uncertainty about the company's future performance. Recent institutional ratings show a mix of actions, with some firms like RBC Capital and Evercore ISI maintaining Outperform ratings, while Deutsche Bank downgraded from Buy to Hold in February 2026, reflecting a cautious stance. Overall, the analyst community is constructive but not overly aggressive, with a consensus that leans bullish but acknowledges risks.
Bulls vs Bears: EMR Investment Factors
Emerson presents a balanced risk/reward profile. The bull case is supported by a reasonable forward PE, improving margins, and a strategic focus on automation, while the bear case highlights a high trailing PE, wide analyst target dispersion, and recent underperformance relative to the market. Currently, the evidence slightly favors the bull case, as the forward valuation is not excessive and the company is executing well on its transformation. The most critical tension is whether Emerson can deliver the expected earnings growth (EPS to $10.07) to justify its current valuation; if it does, the stock could re-rate higher, but if it disappoints, the downside to the low target of $104 is significant.
Bullish
- Forward PE below 22x: EMR trades at a forward PE of 21.87x, which is reasonable for a company with expected EPS growth to $10.07 (analyst consensus). This implies a PEG of 1.78, suggesting the stock is not overvalued relative to its growth prospects.
- Strong margin expansion: Operating margin improved to 19.6% in Q2 FY2026 (from 19.4% in Q2 FY2025), and net margin rose to 13.5% (from 10.9% a year ago). This demonstrates successful execution of margin initiatives and operational leverage.
- Positive analyst sentiment: With 27 analysts, the consensus rating is 'Buy' (mean score 1.93), and the average target price of $163.48 implies about 4.2% upside from the current price of $156.91. The high target of $203 suggests 29.4% upside if the bull case plays out.
- Strategic pivot to automation: Emerson's divestiture of climate and consumer businesses has transformed it into a pure-play industrial automation company. This focus on high-growth, high-margin software and systems (Software and Systems segment revenue of $1.503B in Q2) positions it well for the factory automation trend.
Bearish
- High trailing PE at 32.2x: The trailing PE of 32.23x is elevated, reflecting that the market has already priced in significant earnings growth. If the expected EPS growth to $10.07 does not materialize, the stock could face de-rating.
- Wide analyst target dispersion: Analyst targets range from $104 to $203, a spread of nearly 100%. This wide dispersion indicates significant uncertainty about Emerson's future performance, with the low target implying a 33.7% downside from current levels.
- Negative relative strength vs S&P 500: Over the past year, EMR gained 17.16% while the S&P 500 gained 21.46%, underperforming by about 4.3 percentage points. Over six months, EMR is down 0.3% while the S&P is up 11.29%, showing significant underperformance.
- High debt-to-equity ratio: Debt-to-equity stands at 0.68, which is relatively high for an industrial company. This increases financial risk, especially if interest rates remain elevated or if the company needs to refinance debt.
EMR Technical Analysis
Emerson's stock is in a clear recovery phase, having rebounded strongly from its 52-week low of $122.64. Over the past year, the stock has gained 17.16%, and it currently trades at $156.91, which is approximately 95% of its 52-week range (from $122.64 to $165.15). This positioning near the upper end of the range suggests that the stock has regained significant momentum and is approaching its previous highs, indicating a constructive technical setup. However, the stock remains about 5% below its 52-week high of $165.15, leaving room for a potential breakout if buying pressure persists.
Beta
1.24
1.24x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$165
Price range past year
Annual Return
+19.6%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +14.3% | +2.4% |
| 3m | +15.6% | +4.7% |
| 6m | +2.6% | +11.7% |
| 1y | +19.6% | +21.3% |
| ytd | +16.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Emerson's revenue trajectory shows steady growth, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting revenue of $4.562 billion, up 2.93% year-over-year. This follows a pattern of sequential growth, with Q1 FY2026 revenue of $4.346 billion and Q4 FY2025 revenue of $4.855 billion, indicating a stable but moderate growth rate. The company's growth is being driven by its Intelligent Devices segment, which contributed $2.512 billion in revenue, and Software and Systems, which added $1.503 billion, while Safety and Productivity contributed $0.547 billion. The revenue growth, though modest, reflects resilience in industrial demand and the success of Emerson's automation-focused strategy.
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
53.1%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given Emerson's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 32.23x, while the forward PE is 21.87x, indicating that the market expects significant earnings growth in the coming year. The gap between trailing and forward PE suggests that analysts anticipate a substantial improvement in profitability, likely driven by margin expansion and operational efficiencies. This forward multiple is more reasonable and aligns with the company's growth prospects.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson carries a debt-to-equity ratio of 0.68, which is moderate but not negligible. Interest expenses were $110 million in Q2 FY2026, and with rising interest rates, this could pressure net income. The company's current ratio of 0.88 indicates that current liabilities exceed current assets, suggesting potential liquidity concerns. However, strong free cash flow of $3.115 billion TTM provides a cushion. Revenue growth is modest at 2.93% YoY, and the company relies heavily on the Intelligent Devices segment (55% of revenue), creating concentration risk if that segment underperforms.
FAQ
The key risks for EMR are: 1) Financial risk from a debt-to-equity ratio of 0.68 and a current ratio of 0.88, which could strain liquidity in a downturn. 2) Competitive risk from major players like Siemens and ABB, which could pressure margins. 3) Macro risk from its beta of 1.235, making it more volatile than the market. 4) Company-specific risk from the integration of recent acquisitions and the success of its automation strategy. The most severe risk is a global recession, which could lead to a 33.7% drop to the low target of $104.
The 12-month forecast for EMR is moderately positive. The base case (50% probability) targets a price range of $150-$170, with an average target of $163.48. The bull case (25% probability) targets $175-$203, while the bear case (25% probability) targets $104-$130. The most likely scenario is the base case, assuming steady growth and stable macro conditions. The key assumption is that Emerson achieves its EPS estimate of $10.07. If it exceeds, the stock could reach the high target; if it falls short, the stock could drop to the low target.
EMR is fairly valued based on forward metrics. The forward PE of 21.87x is in line with industrial peers, and the PEG ratio of 1.78 suggests reasonable growth-adjusted valuation. However, the trailing PE of 32.23x is elevated, indicating that the market expects significant earnings growth. Compared to its own history, the stock is trading near the higher end of its valuation range. The market is pricing in an EPS of $10.07 for the next year, which implies a 47% increase from current EPS. If this growth is achieved, the valuation is justified; otherwise, the stock could be considered overvalued.
EMR is a good buy for investors with a medium-term horizon who believe in the industrial automation trend. The stock offers a forward PE of 21.87x, which is reasonable given expected EPS growth to $10.07. The analyst consensus is 'Buy' with an average target of $163.48, implying about 4.2% upside. However, the wide target range ($104-$203) indicates significant uncertainty. The biggest downside risk is a 33.7% drop to the low target if earnings disappoint. For risk-tolerant investors, the current price offers a balanced entry point, but it's not a deep value opportunity.
EMR is more suitable for long-term investment due to its moderate growth and reasonable valuation. The stock has a beta of 1.235, indicating higher volatility, which may not suit short-term traders. The company's transformation into a pure-play automation player provides a secular growth opportunity that should play out over several years. With a dividend yield of 1.61% and a payout ratio of 52%, it offers some income. A minimum holding period of 3-5 years is recommended to allow the automation strategy to drive earnings growth and margin expansion. Short-term trading could be profitable during market upswings, but the stock's volatility and modest growth make it less ideal for quick gains.